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immunofluorometric assay for the 
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ABSTRACT
Objective: In the last decade, data published stressed the role of highly-sensitive thyroglobulin 
(Tg) assays in the follow-up of differentiated thyroid carcinoma (DTC) patients. The present stu-
dy describes a new, highly-sensitive Tg assay, compares it with an available commercial assay, 
and validates it in the follow-up of DTC patients. Subjects and methods: The immunofluoro-
metric high-sensitivity Tg assay is based on monoclonal and polyclonal antibodies produced 
at our laboratories. It was validated in 100 samples of 87 patients with DTC submitted to total 
thyroidectomy, 87% of whom also received radioiodine. For correlation, all samples were also tes-
ted using a commercial Tg assay (Beckman Access) with functional sensitivity (FS) of 0.1 ng/mL. 
Results: The new method showed FS of 0.3 ng/mL. The correlation between the two methods 
was good (r = 0.74; p < 0.0001). The diagnostic sensitivity was 88.9%, and it was increased to 
100% when combined with neck US. Conclusion: This new, high-sensitivity Tg assay presented 
a good correlation with Beckman Access assay and with the clinical outcome of the patients. The 
continuous availability of a validated assay is an additional advantage for long term follow-up 
of DTC patients. Arq Bras Endocrinol Metab. 2012;56(9):658-65
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RESUMO
Objetivo: Na última década, estudos mostraram a importância dos ensaios de tiroglobulina (Tg) 
com melhor sensibilidade funcional no seguimento dos pacientes com carcinoma diferenciado 
de tiroide (CDT). Neste estudo, descrevemos o desenvolvimento de um novo ensaio de Tg de 
alta sensibilidade, que foi validado no seguimento de pacientes com CDT e correlacionado com 
um ensaio comercialmente disponível. Sujeitos e métodos: O ensaio imunofluorométrico de Tg 
baseia-se em anticorpos, um monoclonal e um policlonal desenvolvidos em nosso laboratório. 
Avaliamos 100 amostras de soro de 87 pacientes com CDT submetidos à tiroidectomia total, 
sendo que 87% deles também receberam 131I. A Tg foi dosada também em ensaio comercial 
(Beckman Access). Resultados: A correlação entre os dois métodos foi de 0,74 (p < 0,0001). O 
novo ensaio mostrou uma sensibilidade funcional de 0,3 ng/mL. A sensibilidade diagnóstica foi 
de 88,9%, que aumentou para 100% quando associada ao ultrassom cervical (US). Conclusão: 
O novo método de dosagem de Tg mostra boa correlação com o ensaio comercial Beckman 
Access e com a evolução clínica dos pacientes. O novo ensaio será fundamental no seguimento 
dos nossos pacientes com CDT. Arq Bras Endocrinol Metab. 2012;56(9):658-65
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INTRODUCTION
T hyroglobulin (Tg) is a glycoprotein secreted ex-clusively by thyrocytes into the lumen of thyroid 
follicles. It is the precursor of the thyroid hormones and 
the major component of the thyroid colloid. The main 
form of Tg is a 660-kDa dimer composed of two identi-
cal 330-kDa monomers. Human Tg gene is located on 
the long arm of chromosome 8, encoding 2,767 ami-
no acid residues that, when transcripted, originate the 
monomer (1). Tg goes to extensive post-translational 
modifications, including glycosylation, iodination and 
polymerization, all contributing to marked heteroge-
neity within the colloid. Reduction and degradation 
also lead to the formation of smaller polypeptides (2). 
Formation of thyroid hormones occurs within the Tg 
molecule, and they are secreted in the circulation af-
ter Tg contained in the colloid undergoes enzymatic 
degradation, following a micropinocytosis process by 
the thyrocytes. This process is under direct TSH con-
trol, but degradation is not the only fate of Tg. It can 
also be recycled back into the colloid, or secreted via 
transcytosis. This late process is mediated by binding to 
megalin, a member of the LDL receptor family, and it is 
one of the mechanisms responsible for the presence of 
significant levels of circulating Tg (2). This pathway is 
now recognized as a control mechanism of thyroid hor-
mone release (3). Binding of Tg to megalin depends 
on conformation, and the degree of iodination, which 
has conformational consequences, is one of the mecha-
nisms that alter serum Tg levels independently of TSH 
stimulation (4).  
The first practical and sensitive method for serum 
Tg measurement was described in 1973 by Van Herle 
and cols. (5). It was a radioimmunoassay that used ra-
dioactive iodine-labeled human Tg and an antibody 
generated in rabbits against the same Tg preparation 
used for labeling. Since then, Tg measurement has 
been used for the evaluation of the presence of thyroid 
tissue, mainly in the follow-up of patients diagnosed 
with differentiated thyroid cancer (DTC) (6,7).
Evolution of the methodology was constant in 
these almost four decades, and now we have access to 
assays that are more sensitive, fast, automated, precise 
and commercially available. Nevertheless some chron-
ic problems still plague Tg measurement and can be 
divided in two groups: one derived from the hetero-
geneity of circulating Tg, and the other derived from 
the possible presence of endogenous anti-mouse IgG 
(HAMA) and anti-Tg antibodies (anti-Tg). In the first 
case, the problem is related to the complex metabo-
lic pathway of Tg, as described above. Polyclonal and 
monoclonal antibodies used in immunoassays reco-
gnize Tg epitopes present in the immunization prepa-
ration used to generate them, and these forms may not 
be predominant in a serum sample. Recent studies have 
shown that available assays may differ significantly in 
the levels of Tg detected (8,9), and the search for the 
ideal assay is still a challenge (10).
The presence of HAMA and/or anti-Tg antibo dies 
is the other conundrum of Tg assays. HAMA is a po-
tential problem for all immunometric assays, since most 
of them are based on monoclonal antibodies produced 
in mice. In the case of Tg assays, as in most other im-
munometric assays, the presence of HAMA can lead to 
false-positive (most of the time), or false-negative re-
sults (11,12). The potential presence of HAMA is still 
a challenge, but accumulated knowledge has paved the 
way to deal adequately with the phenomenon most of 
the time (13). The presence of endogenous anti-Tg 
antibodies is, in Tg assays, an even more complex pro-
blem, generating false-negative results. The high fre-
quency of anti-Tg antibodies in the general population, 
particularly in patients with DTC, and  the difficulty 
of standardizing assays to detect anti-Tg antibodies, 
makes the problem even more complex (14-17). Com-
petitive assays for Tg do not seem to be too sensitive 
to this problem, but they are no longer used in clinical 
laboratories, being available only in few research labo-
ratories (15).
In this paper, we describe the development of a sen-
sitive immunofluorometric Tg assay based on a rabbit 
polyclonal antibody and a mouse monoclonal antibody 
anti-Tg. We describe its characterization and clinical 
validation in serum samples of patients with DCT with 
negative and positive anti-Tg antibodies. Correlation 
with a commercial automated immunometric assay is 
also provided.
PATIENTS 
We evaluated this new assay in 87 DTC patients who 
were followed up by a single team of physicians at the 
associated Thyroid Disease Centers at the Division of 
Endocrinology, Department of Medicine, Escola Pau-
lista de Medicina, Universidade Federal de São Paulo 
and at the Instituto Israelita de Ensino e Pesquisa Al-
bert Einstein, both in Sao Paulo, Brazil. All the diag-
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nostic procedures were performed in accordance with 
the guidelines determined by the local Ethics Commit-
tee. Written informed consent was obtained from all 
the patients.
All patients had been treated with total or near-
total thyroidectomy and 76/87 had also received 131I 
ablation or treatment (30 to 750 mCi) for the thyroid 
remnant. Patients were 78 women and 9 men, with 
mean age at diagnosis of 40 years old (19 to 79 years 
old), 79 with papillary thyroid carcinoma (PTC), and 8 
with follicular thyroid carcinoma (FTC). Mean time of 
follow-up was 52 months (21 to 80 months) after Tg 
measurements. Patients were classified, for better data 
analysis, as follows: 
1) Group 1 (n = 42): 42 patients ‘without evidence of 
disease or thyroid tissue remnant’, when there was 
no evidence of disease or thyroid tissue remnant, 
either clinically or in laboratorial and imaging tests 
(stimulated Tg levels < 1.0 ng/mL, negative whole 
body scan - WBS -, and neck US negative for suspi-
cious images). 
2) Group 2 (n = 17): 17 patients ‘without evidence of 
disease and with thyroid tissue remnant’, when they 
had positive thyroid bed uptake on diagnostic or 
post-therapeutic WBS with negative US, and stimu-
lated serum Tg < 10 ng/mL.
3) Group 3 (n = 15): 15 patients ‘with metastasis’, 
when there was evidence of disease in cytological or 
histological analysis, or thyroid bed uptake in WBS.
4) Group 4 (n = 7): 7 patients ‘with metastasis and pos-
itive anti-Tg’, when there was evidence of disease in 
cytological or histological analysis, or thyroid bed 
uptake in WBS with positive serum test for anti-Tg. 
A total of 100 measurements were analyzed, as 
12/87 patients had more than one Tg measurement in 
different periods of follow-up. 
MATERIALS AND METHODS
“In house” Tg assay
Polyclonal antibodies anti-human thyroglobulin were 
produced at our laboratory in rabbits immunized 
with thyroglobulin by the multiple injection protocol 
(18,19). The thyroglobulin preparation used for im-
munization was obtained from human thyroid gland 
collected at surgery from patients submitted to sub-
total thyroidectomy for treatment of Graves’ disease 
(19,20). Purification was based on ammonium sulfa-
te precipitation (19,20), and the antibody (rabbit A2) 
was used in a final dilution of 1/15,000 in Tris-HCL 
50 mM, pH 7.5, with 0.5% BSA and 0.05% of bovine 
gammaglobulin.
Monoclonal antibodies (mAb) anti-human thyro-
globulin were obtained at our laboratory from hybrid-
omas produced from spleen cells collected from mice 
immunized with the same thyroglobulin preparation 
used for the polyclonal antibody production. Stan-
dard immunization and fusion protocols (21) were 
used. Screening (using human thyroglobulin > 97% 
pure purchased from Scripps Laboratories, San Diego, 
CA, USA), selection, ascites production, purification, 
and IgG subtyping followed the same methodology 
described previously (22). Titer and specificity stu dies 
were conducted, and the cell line D6P2, an IgG1 kap-
pa, was selected. 
Monoclonal antibodies anti-rabbit IgG (D4P4, 
IgG1 kappa) were produced at our laboratory by the 
same protocol described for the thyroglobulin mAb 
production. Mice were immunized with rabbit serum 
IgG, > 95% pure, purchased from Sigma-Aldrich, St. 
Louis, MO, USA. This mAb was biotinylated with N-
hydroxysuccinimide-biotin (NHS-biotin, Pierce, Rock-
ford, IL, USA) (23). After dialysis purification, the bio-
tinylated mAb was used at a final dilution of 1/2,000 
in the same buffer used for the rabbit anti-Tg mAb with 
the addition of 1% normal mouse serum.
Europium-labeled streptavidin (Perkin Elmer, Turku, 
Finland) was used at a 1/2,000 dilution and fluorome-
try measured using a time-resolved fluorometer (Perkin 
Elmer, Turku, Finland). Standard curve was produced 
by serial dilution of human thyroglobulin reference 
standard CRM 457 (Institute for Reference Materials 
and Measurements, European Comission, Geel, Be l-
gium) in a pool of sera from patients with previous un-
detectable levels of thyroglobulin and anti-thyroglobu-
lin antibodies. This serum pool was previously treated 
with charcoal, centrifuged, and filtered through a 0.45-
µm filter (Millipore, USA). The standard curve ranged 
from 400 to 0.78 ng/mL.
Serum samples from patients from our Thyroid Dis-
eases Centers were obtained by venipuncture and after 
serum separation, stored at -20°C until analysis. 
“In house” Assay Protocol
The wells of microtiter plates (96-well FluoroNunc, 
Nunc, Roskilde, Denmark) were coated with 200 µL of 
a solution of the anti-Tg mAb (D6P2), 10 µg/mL in 
20 mM PBS, pH 7.4. After an overnight incubation at 
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4oC, wells were washed three times with washing buffer 
(PBS, pH 7.4 with 0.05% Tween 20) and treated with 
200 µL of Tris-HCl 50 mM, pH 7.75, containing 0.5% 
BSA and 0.05% bovine gammaglobulin, for 1 hour at 
37oC. Plates were emptied by inversion and after a new 
washing procedure, 100 µL of sample or standard curve 
were pipetted in duplicate, followed by 100 µL of the 
polyclonal rabbit anti-Tg antibody at a final dilution of 
1/5,000 in Tris-HCl 50 mM pH 7.75 with 0.5% BSA 
and 0.05% bovine gammaglobulin. Plates were shaken 
in a horizontal shaker for 1h at room temperature, sea-
led, and incubated for 48h at 4oC. 
After the incubation and new washing procedure, 200 
µL of a 1/2,000 dilution of the biotinylated anti-rabbit 
IgG mAb was added, plates agitated for 2h at room tem-
perature, washed, and 200 µL of a 1/2,000 dilution of 
europium-labeled streptavidin (PerkinElmer, Turku, Fin-
land) was added. After 30 minutes of incubation under 
agitation, plates were washed and 200 µL of fluorescent 
solution (PerkinElmer) were added, with time-resolved 
fluorescence read after 5 minutes of agitation.
Tg Beckman Access immunoassay
The Tg Access assay (Beckman Coulter, Fullerton, CA, 
USA) is an one-step “sandwich” assay. A sample is ad-
ded to a reaction vessel along with a mixture of four 
biotinylated monoclonal anti-Tg antibodies, streptavi-
din-coated paramagnetic particles, and a monoclonal 
anti-Tg antibody alkaline phosphatase conjugate. The 
biotinylated antibodies bind to the solid phase and se-
rum thyroglobulin binds to these antibodies, while the 
conjugate antibody reacts with a different antigenic site 
on the thyroglobulin molecules. After incubation in a 
reaction vessel for 42 minutes, materials bound to the 
solid phase are held in a magnetic field while unbound 
materials are washed away. A chemiluminescent subs-
trate, Lumi-Phos** 530 is added to the reaction vessel 
and light generated by the reaction is measured with a 
luminometer. Light production is directly proportional 
to the concentration of thyroglobulin in the sample. 
The amount of Tg in the sample is determined by com-
parison with a stored, multipoint calibration curve.
RESULTS
Characteristics of the assays
“In house” assay: analytical sensitivity was 0.07 ng/mL; 
intra-assay CV was 7.2% for a pool with a mean value 
of 0.67 ng/mL, 3.7% for a pool with a mean value of 
2.9 ng/mL, and 4.9% for a pool with a mean value of 
158.0 ng/mL. Inter-assay CV was 15.8%, 12.5%, and 
10.8% for the same pools. Functional sensitivity (FS) of 
the assay was 0.3 ng/mL.
Beckman Access assay: analytical sensitivity was 0.01 
ng/mL; intra-assay CV was 1.4% for a pool with a mean 
value of 4.2 ng/mL, 1.4% for a pool with a mean value 
of 21.6 ng/mL, 4.4% for a pool with a mean value of 
130.4 ng/mL, and 2.0% for a pool with a mean value 
of 344.7 ng/mL. Inter-assay CV was 1.7%, 1.8%, 4.9% 
and 4.0% for the same pools. Total CV was 4.9% for a 
pool with a mean value of 4.2 ng/mL, 5.2% for a pool 
with a mean value of 5.3 ng/mL, 6.4% for a pool with 
a mean value of 34.0 ng/mL, 3.8% for a control with 
a mean value of 42.5 ng/mL, and 4.6% for a control 
with a mean value of 213.0 ng/mL. FS of the assay was 
0.1 ng/mL.
Clinical data
Correlation between both methods in all 100 measure-
ments (87 patients) was considered good with r = 0.74 
(p < 0.0001) and is shown in figure 1.
The analysis of the 42 patients ‘without evidence 
of disease or thyroid tissue remnant’ (Group 1), has 
shown that Tg was undetectable in 40/42 patients us-
ing the Beckman Access assay, and in 36/42 with our 
“in house” method. Therefore, a total of 7 of these 42 
patients had detectable levels of Tg in one or both as-
says, but they were in low levels: maximum Tg values 
were 0.9 ng/mL with Beckman Access, and 0.8 ng/
100
10
1
0.3
0.1
0.01 0.1 1 10 100
Tg Access
Tg
 in
 h
ou
se
Figure 1. Correlation between both methods in 100 measurements (all 
87 patients), r = 0.74 (p < 0.0001).
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mL with our assay (Figure 2). During the follow-up of 
these 7 patients, Tg became undetectable in 5 of them.
The analysis of the 17 patients with evidence of ‘thy-
roid tissue remnant’ (Group 2) showed that 16/17 had 
detectable Tg with the “in house” methodology, and 
11/17 with the Beckman Access assay, showing that 
these assays are very sensitive for the presence of thy-
roid tissue. From those 16 patients with detectable Tg 
in our method, 7 had received 30 mCi of radioiodine 
for thyroid ablation, and 7 had not received radioio-
dine. All 17 patients were considered without evidence 
of disease during the period of follow-up of at least 40 
months (Table 1). 
The evaluation of 15 patients ‘with metastasis and 
negative TgAb antibodies’ (Group 3) showed that Tg 
was detectable in 13/15 patients with both methods, a 
diagnostic sensitivity of 88.9% with both methods, which 
increased to 100% when combined with neck US. The 
correlation between methods in this group of patients 
was also good (r = 0.77 and p < 0.0001) (Figure 3). 
On the other hand, Tg was undetectable with both 
methods in all 7 patients with ‘metastasis and positive 
anti-Tg’ (Group 4), showing, as expected, antibody in-
terference. 
Our method showed a 42.1% positive predictive val-
ue (PPV), 94.7% negative predictive value (NPV) and 
68.4% accuracy when all measurements were evaluated 
(Table 2). When patients with evidence of thyroid tis-
sue remnant were excluded, a 68.4% positive predictive 
value (PPV), a 94.7% negative predictive value (NPV), 
and 86% accuracy were observed (Table 3). These data 
show that our method also detects the presence of Tg 
from minimal thyroid remnants. Figure 2. Patients without evidence of disease or thyroid tissue remnant.
1.0
0.6
0.3
0.0
0.0 0.2 0.4 0.6 0.8 1.0
(ng/mL)
Tg
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Table 1. Clinical and laboratory data of 17 patients with evidence of ‘thyroid tissue remnant’ 
Patient Gender
Age at
diagnosis 
(years)
TNM
131I activity before 
measurement of 
Tg
(mCI)
Tg access Tg in house US WBS
Follow-up 
(months)
Actual 
status
1 F 26 T2N0M0 0 < 0.1 0.4 neg TB 79 NED
2 F 47 TxN0M0 0 < 0.1 2.1 neg TB 59 NED
3 F 45 T2N0M0 0 0.6 < 0.3 neg TB 40 NED
4 F 24 T3N0M0 0 0.6 0.6 neg TB 72 NED
5 F 29 T1N0M0 0 0.6 1.0 neg TB 58 NED
6 F 47 T1N0M0 0 1.4 2.4 neg TB 49 NED
7 F 42 T1N0M0 0 1.5 3.4 neg TB 58 NED
8 F 55 T3N0M0 30 < 0.1 0.5 neg TB 40 NED
9 F 30 T3N0M0 30 < 0.1 1.4 neg TB 77 NED
10 F 32 T1N0M0 30 < 0.1 1.6 neg TB 50 NED
11 F 31 T1N0M0 30 0.4 1.3 neg TB 49 NED
12 F 60 T1N0M0 30 0.4 2.2 neg TB 43 NED
13 F 22 T2N0M0 30 0.7 0.9 neg TB 77 NED
14 F 36 T1N0M0 30 0.7 2.3 neg neg 43 NED
15 F 58 T2N0M0 100 1.5 3.4 neg TB 50 NED
16 F 31 T1N0M0 150 0.6 2.3 neg TB 46 NED
17 M 36 T2N0M0 350 < 0.1 0.4 neg TB 42 NED
F: female; M: male; neg: negative; WBS: whole body scan; TB: thyroid bed; NED: none evidence of disease.
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DISCUSSION
First, why develop a new Tg assay? Besides having the 
know-how for this development, we were mostly driven 
by the possibility of having access to the same assay for 
a long period of time. As seen, commercial assays are 
constantly modified in order to improve performance, 
which is a good tendency, but differences in the recog-
nition of Tg molecules can vary along the way. Besides, 
development is costly and it is cheaper to maintain an 
“in house” diagnostic routine test. Also, the study and 
the possible minimization of interference with anti-Tg 
and heterophilic antibodies can be further studied and 
potentially optimized. 
Another point of interest is the between-method 
variability, because despite the introduction of a thy-
roglobulin reference material (CRM 457), current 
methods still have significant between-assay variability, 
and immunometric assays (IMA) vary more than the 
competitive radioimmunoassays (RIA). This difference 
probably derives from the fact that RIA methods use 
polyclonal antibodies with wide epitope specificities 
that have the potential to measure a larger range of ab-
normal tumor-derived thyroglobulin isoforms, in con-
trast with IMA methods, which employ monoclonal 
antibodies with restricted epitope specificities (8,24). 
Our method has the advantage of employing mono-
clonal and polyclonal antibodies resulting in potential 
detection of a wider range of epitopes. 
Also, the processes of Tg formation within follicular 
cells can be modified in thyroid neoplasms, resulting in 
conformational changes in the secreted Tg molecules 
(25). Considering the conformational nature of Tg 
epitopes (26), probably IMA methods detect differ-
ent and more restricted Tg isoforms, resulting in wider 
between-method bias when measuring tumor-derived 
Tg as compared with non-tumor Tg (8).  
The American, European and Brazilian Thyroid As-
sociation guidelines suggest that a patient with DTC 
can be considered free of disease when there is no clini-
cal and no imaging evidence of tumor, and Tg is unde-
tectable during TSH suppression and following TSH 
stimulation (27-29). However, some authors have 
shown that TSH stimulation is not necessary when us-
ing second generation Tg assays with functional sensi-
tivity of 0.1 to 0.3 ng/mL (30-32).
Our method has functional sensitivity (FS) of 0.3 
ng/mL and has shown good sensitivity and high NPV. 
The 42.1% of PPV was probably caused by patients 
with evidence of thyroid tissue remnant, and because 
we arbitrarily defined the Beckman Access method as 
the ‘gold standard’. Our performance would be much 
better if it was the other way around: with our method 
as the ‘gold standard’, because 16/17 patients with evi-
dence of ‘thyroid tissue remnant’ on whole body scan 
had detectable Tg with our methodology, and 12/17 
with the Beckman Access Assay. In this group of pa-
tients with evidence of ‘thyroid tissue remnant’, 7/17 
have not received radioiodine for thyroid ablation and 
7/17 have received 30 mCi radioiodine for thyroid ab-
lation, showing that our assay is very sensitive for the 
presence of thyroid tissue, probably due to the use of 
polyclonal antibodies. All 17 patients had negative US 
and at least 40 months of follow-up without evidence 
of disease. Most importantly, Tg values decreased in 
most patients or remained at the same level in others. 
Therefore, clinicians should be aware of this feature, 
Figure 3. Correlation between both methods in 18 measurements (all 15 
patients with metastasis and negative anti-Tg), r = 0.77 (p < 0.0001).
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Table 2. Sensitivity, specificity, VPP, VPN and accuracy of both methods in 
all measurements
Method Sensitivity Specificity PPV PNV Accuracy
Beckman 88.9% 77.6% 55.2% 95.7% 80.3%
In house 88.9% 62.1% 42.1% 94.7% 68.4%
Table 3. Sensitivity, specificity, VPP, VPN and accuracy of both methods 
excluding patients with evidence of thyroid remnants 
Method Sensitivity Specificity PPV PNV Accuracy
Beckman 86.7% 95.2% 86.6% 95.2% 93%
In house 86.7% 85.7% 68.4% 94.7% 86%
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because many patients with thyroid tissue remnant will 
have Tg measured with assays with better functional 
sensitivity. A Tg ‘trend’ may be more important than a 
single measurement, because rising Tg values over time 
raise the suspicion of growing thyroid tissue or recur-
rence of disease (27).
The new method detected almost all patients with 
metastasis in patients with negative anti-Tg and sup-
pressed TSH, and reached 100% sensitivity when com-
bined with neck US and cytology.
Interference caused by heterophilic antibodies 
(HAMA) is a potential problem for all assays employ-
ing IMA methodology and mouse monoclonal anti-
body reagents (11). HAMA interference arises when 
antibodies that recognize murine proteins are present 
in the patient serum and interact with the capture and/
or labeled monoclonal antibody reagents. These re-
actions simulate the presence of thyroglobulin in the 
specimen, and can create a falsely elevated result and, 
rarely, a false-negative result (12,33). Our assay uses 
antibodies derived from rabbit (polyclonal) and mouse 
(monoclonal), which potentially decrease the interfer-
ence by heterophilic antibodies, because it is more un-
usual that one patient has antibodies reacting against 
immunoglobulins from two different species. 
As expected, patients with positive anti-Tg antibo-
dies are still a challenge for immunometric Tg assays. 
The interference caused by anti-Tg antibodies remains 
the most serious problem limiting the clinical utility of 
Tg testing, and we did not overcome that for now. In 
our study, 7 patients with metastasis and positive anti-
Tg had undetectable Tg with both assays. Having con-
tinuous access to the same methodology, we will be 
able to study alternatives in order to deal with the inter-
ference of these antibodies in our assay. Until now, to 
prevent interference by TgAb, we and others have de-
veloped qualitative RT-PCR assay to amplify mRNA Tg 
present in circulating thyroid cells from patients with 
DT, allowing differentiation between patients “free of 
disease” and those with metastases (34,35). Therefore, 
mRNA Tg could be an appropriate molecular marker 
for the follow-up of patients with thyroid carcinoma, 
especially in patients with positive TgAb.
In conclusion, this new method of Tg measurement 
could represent an improvement in terms of sensitivity 
when compared with the most widely employed assays 
in our country. Moreover, the use of antibodies from 
two different species in this new assay possibly decrea-
ses the potential interference of heterophilic antibodies. 
Further, we will be able to rely on the same method 
in our clinical setting for long term follow-up of DTC 
patients and study alternatives to deal with the interfer-
ence of anti-Tg antibodies.
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